These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 34433022)

  • 41. Comparison of effects of p53 null and gain-of-function mutations on salivary tumors in MMTV-Hras transgenic mice.
    Jiang D; Dumur CI; Massey HD; Ramakrishnan V; Subler MA; Windle JJ
    PLoS One; 2015; 10(2):e0118029. PubMed ID: 25695772
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zeb1 in Stromal Myofibroblasts Promotes
    Sangrador I; Molero X; Campbell F; Franch-Expósito S; Rovira-Rigau M; Samper E; Domínguez-Fraile M; Fillat C; Castells A; Vaquero EC
    Cancer Res; 2018 May; 78(10):2624-2637. PubMed ID: 29490942
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Black raspberries suppress pancreatic cancer through modulation of NKp46
    Pan P; Zhu Z; Oshima K; Aldakkak M; Tsai S; Huang YW; Dong W; Zhang J; Lin CW; Wang Y; Yearsley M; Yu J; Wang LS
    Food Front; 2020 Mar; 1(1):70-82. PubMed ID: 32368735
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer.
    Fendrich V; Sparn M; Lauth M; Knoop R; Plassmeier L; Bartsch DK; Waldmann J
    Pancreatology; 2013; 13(5):502-7. PubMed ID: 24075515
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rb and p53 Execute Distinct Roles in the Development of Pancreatic Neuroendocrine Tumors.
    Yamauchi Y; Kodama Y; Shiokawa M; Kakiuchi N; Marui S; Kuwada T; Sogabe Y; Tomono T; Mima A; Morita T; Matsumori T; Ueda T; Tsuda M; Nishikawa Y; Kuriyama K; Sakuma Y; Ota Y; Maruno T; Uza N; Masuda A; Tatsuoka H; Yabe D; Minamiguchi S; Masui T; Inagaki N; Uemoto S; Chiba T; Seno H
    Cancer Res; 2020 Sep; 80(17):3620-3630. PubMed ID: 32591410
    [TBL] [Abstract][Full Text] [Related]  

  • 46. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer.
    Cappello P; Rolla S; Chiarle R; Principe M; Cavallo F; Perconti G; Feo S; Giovarelli M; Novelli F
    Gastroenterology; 2013 May; 144(5):1098-106. PubMed ID: 23333712
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Overall survival of pancreatic ductal adenocarcinoma is doubled by
    Lee JS; Lee H; Woo SM; Jang H; Jeon Y; Kim HY; Song J; Lee WJ; Hong EK; Park SJ; Han SS; Kim SY
    Theranostics; 2021; 11(7):3472-3488. PubMed ID: 33537098
    [No Abstract]   [Full Text] [Related]  

  • 49. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells.
    Diersch S; Wirth M; Schneeweis C; Jörs S; Geisler F; Siveke JT; Rad R; Schmid RM; Saur D; Rustgi AK; Reichert M; Schneider G
    Oncogene; 2016 Jul; 35(29):3880-6. PubMed ID: 26592448
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neutrophil in the Pancreatic Tumor Microenvironment.
    Jin L; Kim HS; Shi J
    Biomolecules; 2021 Aug; 11(8):. PubMed ID: 34439836
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.
    Jiang H; Hegde S; Knolhoff BL; Zhu Y; Herndon JM; Meyer MA; Nywening TM; Hawkins WG; Shapiro IM; Weaver DT; Pachter JA; Wang-Gillam A; DeNardo DG
    Nat Med; 2016 Aug; 22(8):851-60. PubMed ID: 27376576
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transgenic mouse model expressing P53(R172H), luciferase, EGFP, and KRAS(G12D) in a single open reading frame for live imaging of tumor.
    Ju HL; Calvisi DF; Moon H; Baek S; Ribback S; Dombrowski F; Cho KJ; Chung SI; Han KH; Ro SW
    Sci Rep; 2015 Jan; 5():8053. PubMed ID: 25623590
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer.
    Dosch JS; Ziemke EK; Shettigar A; Rehemtulla A; Sebolt-Leopold JS
    Cancer Res; 2015 Nov; 75(21):4582-92. PubMed ID: 26359451
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hes1 plays an essential role in Kras-driven pancreatic tumorigenesis.
    Nishikawa Y; Kodama Y; Shiokawa M; Matsumori T; Marui S; Kuriyama K; Kuwada T; Sogabe Y; Kakiuchi N; Tomono T; Mima A; Morita T; Ueda T; Tsuda M; Yamauchi Y; Sakuma Y; Ota Y; Maruno T; Uza N; Uesugi M; Kageyama R; Chiba T; Seno H
    Oncogene; 2019 May; 38(22):4283-4296. PubMed ID: 30705405
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aspirin prolongs survival and reduces the number of Foxp3+ regulatory T cells in a genetically engineered mouse model of pancreatic cancer.
    Plassmeier L; Knoop R; Waldmann J; Kesselring R; Buchholz M; Fichtner-Feigl S; Bartsch DK; Fendrich V
    Langenbecks Arch Surg; 2013 Oct; 398(7):989-96. PubMed ID: 23989613
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Inactivation of Brca2 promotes Trp53-associated but inhibits KrasG12D-dependent pancreatic cancer development in mice.
    Rowley M; Ohashi A; Mondal G; Mills L; Yang L; Zhang L; Sundsbak R; Shapiro V; Muders MH; Smyrk T; Couch FJ
    Gastroenterology; 2011 Apr; 140(4):1303-1313.e1-3. PubMed ID: 21199651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pancreatic Premalignant Lesions Secrete Tissue Inhibitor of Metalloproteinases-1, Which Activates Hepatic Stellate Cells Via CD63 Signaling to Create a Premetastatic Niche in the Liver.
    Grünwald B; Harant V; Schaten S; Frühschütz M; Spallek R; Höchst B; Stutzer K; Berchtold S; Erkan M; Prokopchuk O; Martignoni M; Esposito I; Heikenwalder M; Gupta A; Siveke J; Saftig P; Knolle P; Wohlleber D; Krüger A
    Gastroenterology; 2016 Nov; 151(5):1011-1024.e7. PubMed ID: 27506299
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
    Sun H; Zhang B; Li H
    Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IRAK4 Signaling Drives Resistance to Checkpoint Immunotherapy in Pancreatic Ductal Adenocarcinoma.
    Somani VK; Zhang D; Dodhiawala PB; Lander VE; Liu X; Kang LI; Chen HP; Knolhoff BL; Li L; Grierson PM; Ruzinova MB; DeNardo DG; Lim KH
    Gastroenterology; 2022 Jun; 162(7):2047-2062. PubMed ID: 35271824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.